Comparison · NCT02509481-sae
Single MDA vs Repeated MDA: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Single MDA vs Repeated MDA: serious adverse events. Trial comparisons, record NCT02509481-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02509481-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00791 | 0.0043 | 0.0145 | wilson | |
| Risk in group 2 | 0.0131 | 0.00842 | 0.0204 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00523 | -0.0134 | 0.00287 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.602 | 0.281 | 1.29 | log | |
| Odds ratio, group 1 over group 2 | 0.599 | 0.277 | 1.29 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Single MDA than on Repeated MDA | 191 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Single MDA | Single mass drug administration of ivermectin (150 µg/kg) + albendazole (400 mg) performed after the start of the rainy season as part of public health efforts to eliminate lymphatic filariasis.~Ivermectin~Albendazole | 10 | 1,265 | EG000 |
| Group 2 | Repeated MDA | Same as Active Comparator, but then followed by five more mass drug administrations of ivermectin only (150 µg/kg) every three weeks thereafter.~Ivermectin~Albendazole | 19 | 1,447 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
- NCT number
- NCT02509481
- Phases
- PHASE2, PHASE3
- Conditions
- Malaria, Lymphatic Filariasis
- Interventions
- Ivermectin, Albendazole
- Lead sponsor
- Colorado State University
- Results first posted
- 2019-01-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02509481?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02509481-sae